These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21669382)

  • 21. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
    Danese MD; Badamgarav E; Bauer DC
    J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fracture risk, new treatments: how does the management of the osteoporosis of elderly change?].
    Aubry-Rozier B; Lamy O
    Rev Med Suisse; 2010 Mar; 6(240):569-70, 572-4. PubMed ID: 20408462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First Fracture Project: addressing the osteoporosis care gap.
    Vaile J; Sullivan L; Bennett C; Bleasel J
    Intern Med J; 2007 Oct; 37(10):717-20. PubMed ID: 17894768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?
    Sanders KM; Nicholson GC; Watts JJ; Pasco JA; Henry MJ; Kotowicz MA; Seeman E
    Bone; 2006 May; 38(5):694-700. PubMed ID: 16507356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost and Consequences of Nonadherence With Oral Bisphosphonate Therapy: Findings From a Real-World Data Analysis.
    Sharman Moser S; Yu J; Goldshtein I; Ish-Shalom S; Rouach V; Shalev V; Modi A; Chodick G
    Ann Pharmacother; 2016 Apr; 50(4):262-9. PubMed ID: 26783359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Women with cardiovascular disease have increased risk of osteoporotic fracture.
    Chen JS; Hogan C; Lyubomirsky G; Sambrook PN
    Calcif Tissue Int; 2011 Jan; 88(1):9-15. PubMed ID: 21046091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
    Rabenda V; Hiligsmann M; Reginster JY
    Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
    Siris ES; Baim S; Nattiv A
    Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial.
    Montori VM; Shah ND; Pencille LJ; Branda ME; Van Houten HK; Swiglo BA; Kesman RL; Tulledge-Scheitel SM; Jaeger TM; Johnson RE; Bartel GA; Melton LJ; Wermers RA
    Am J Med; 2011 Jun; 124(6):549-56. PubMed ID: 21605732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reducing fracture risk with calcium and vitamin D.
    Lips P; Bouillon R; van Schoor NM; Vanderschueren D; Verschueren S; Kuchuk N; Milisen K; Boonen S
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):277-85. PubMed ID: 20796001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse outcomes of osteoporotic fractures in the general population.
    Melton LJ
    J Bone Miner Res; 2003 Jun; 18(6):1139-41. PubMed ID: 12817771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
    Siris ES; Selby PL; Saag KG; Borgström F; Herings RM; Silverman SL
    Am J Med; 2009 Feb; 122(2 Suppl):S3-13. PubMed ID: 19187810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
    Martens MG
    J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevalence of osteoporotic fractures in patients treated by androgen blockade for prostate cancer].
    Dahmani L; Wagner B; Auzanneau C; Irani J; Doré B
    Prog Urol; 2003 Feb; 13(1):73-8. PubMed ID: 12703357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [FRAX--model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines].
    Johansson H; Kanis JA; Ljunggren O; Ström O; Svensson O; Mellström D
    Lakartidningen; 2011 Feb 16-22; 108(7):336-9. PubMed ID: 21539116
    [No Abstract]   [Full Text] [Related]  

  • 39. Prevention of osteoporosis and fractures.
    Ullom-Minnich P
    Am Fam Physician; 1999 Jul; 60(1):194-202. PubMed ID: 10414638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study.
    Meier C; Nguyen TV; Center JR; Seibel MJ; Eisman JA
    J Bone Miner Res; 2005 Apr; 20(4):579-87. PubMed ID: 15765176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.